INPUT Slovakiet - slovakisk - myHealthbox

input

bayer ag - emulzný koncentrát - prothioconazole 160 g/l; spiroxamine 300 g/l

INPUT Slovakiet - slovakisk - myHealthbox

input

bayer ag - emulzný koncentrát - prothioconazole 160 g/l; spiroxamine 300 g/l

Xeljanz Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 a 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

BOOGIE XPRO Slovakiet - slovakisk - myHealthbox

boogie xpro

bayer ag - emulgovateľný koncentrát - bixafen 50 g/l; prothioconazole 100 g/l; spiroxamin 250 g/l

PROPULSE Slovakiet - slovakisk - myHealthbox

propulse

bayer ag - suspenzný koncentrát - fluopyram 125 g/l; prothioconazole 125 g/l

REDIGO M Slovakiet - slovakisk - myHealthbox

redigo m

bayer ag - stabilna suspenzia - metalaxyl 20 g/l; prothioconazole 100 g/l

BOOGIE XPRO Slovakiet - slovakisk - myHealthbox

boogie xpro

bayer ag - emulgovateľný koncentrát - bixafen 50 g/l; prothioconazole 100 g/l; spiroxamin 250 g/l

PROPULSE Slovakiet - slovakisk - myHealthbox

propulse

bayer ag - suspenzný koncentrát - fluopyram 125 g/l; prothioconazole 125 g/l

REDIGO M Slovakiet - slovakisk - myHealthbox

redigo m

bayer ag - stabilna suspenzia - metalaxyl 20 g/l; prothioconazole 100 g/l